GlassScriptPhysician profile
Reza Yavari
NPI 1053477703
$8,741.21
in general payments reported to CMS, 2019-2025
23 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,378 · 2020: $805 · 2021: $951 · 2022: $951 · 2023: $1,393 · 2024: $1,235 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,655.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,673.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,512.03 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $1,508.05 | 2021-2025 | Freestyle Libre 3 |
| Insulet Corporation | $968.24 | 2019-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $933.30 | 2019-2022 | |
| Corcept Therapeutics | $530.10 | 2019-2025 | Korlym |
| Tandem Diabetes Care, INC. | $368.86 | 2019-2020 | |
| Antares Pharma, INC. | $291.09 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Abbvie INC. | $284.83 | 2019-2023 | Synthroid, Botox |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.90 | 2019-2024 | Jardiance |
| Ibsa Pharma INC. | $104.98 | 2019-2024 | Tirosint, Licart, Tirosint |
| Astrazeneca Pharmaceuticals LP | $74.71 | 2019-2020 | |
| Halozyme INC | $52.66 | 2023 | |
| Merck Sharp & Dohme LLC | $47.09 | 2019 | |
| Cequr Corporation | $41.86 | 2022-2023 | Cequr Simplicity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $40.31 | 2021-2022 | |
| Amgen INC. | $39.59 | 2022-2024 | Repatha |
| Currax Pharmaceuticals LLC | $29.67 | 2024 | Contrave |
| Aytu Biopharma, INC. | $29.45 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $22.41 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.60 | 2019 | |
| Ascensia Diabetes Care US INC. | $13.90 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reza Yavari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.